
- /
- Supported exchanges
- / US
- / SNY.NASDAQ
Sanofi ADR (SNY NASDAQ) stock market data APIs
Sanofi ADR Financial Data Overview
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sanofi ADR data using free add-ons & libraries
Get Sanofi ADR Fundamental Data
Sanofi ADR Fundamental data includes:
- Net Revenue: 45 166 M
- EBITDA: 12 148 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 0.9548
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi ADR News

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports
FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s...


FDA publishes more than 200 rejection letters in a bid to improve transparency
[US Food and Drug Administration (FDA)] The U.S. Food and Drug Administration (FDA) on Thursday published more than 200 complete response letters ((CRLs)), through which drugmakers are informed about...

Blueprint Medicines stock hits all-time high at 129.49 USD
Blueprint Medicines Corp (NASDAQ:BPMC) stock has reached an all-time high, hitting a price of 129.49 USD. According to InvestingPro data, the stock’s RSI indicates overbought territory, with the pr...

Goldman Sachs initiates Nurix stock with Buy rating, $182 price target
Investing.com - Goldman Sachs initiated coverage on Nurix (NASDAQ:NRIX) with a Buy rating and set a price target of $182.00. Currently trading at $13.18, the stock has shown significant volatility wit...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.